DAX24.416 +0,2%Est505.621 -0,1%MSCI World4.335 -0,4%Top 10 Crypto16,94 -2,7%Nas22.831 -0,5%Bitcoin104.563 -1,9%Euro1,1675 -0,3%Öl65,22 -0,5%Gold3.991 +0,7%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 DroneShield A2DMAA AMD (Advanced Micro Devices) 863186 Plug Power A1JA81 NVIDIA 918422 RENK RENK73 Tesla A1CX3T D-Wave Quantum A3DSV9 NEL ASA A0B733 HENSOLDT HAG000 Novo Nordisk A3EU6F Siemens Energy ENER6Y Bayer BAY001 BASF BASF11 Palantir A2QA4J
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX fester -- US-Börsen uneins -- Norwegen stockt RENK-Anteil auf -- Dell, Novo Nordisk, IBM, AMD, Trilogy Metals, DroneShield, Rheinmetall, HENSOLDT, D-Wave, AppLovin, NEL, Siemens Energy im Fokus
Top News
Dell-Aktie steigt: Prognose wegen starker KI-Nachfrage erhöht Dell-Aktie steigt: Prognose wegen starker KI-Nachfrage erhöht
Heidelberger Druckmaschinen: Die Neubewertung läuft Heidelberger Druckmaschinen: Die Neubewertung läuft
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Johnson Johnson Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
159,88 EUR -1,08 EUR -0,67 %
XETRA
187,72 USD -0,46 USD -0,24 %
BTT
Johnson Johnson jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)
Smartphone

Marktkap.388,86 Mrd. EUR

KGV24,98Div. Rendite3,40%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN853260

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS4781601046

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolJNJ

Johnson Johnson Aktien News

DatumMeistgelesen
PR NewswireRYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer
PR NewswireJohnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis
PR NewswireJohnson & Johnson is transforming solid tumor cancer outcomes with new data at the 2024 World Conference on Lung Cancer and European Society for Medical Oncology Congress
PR NewswireRYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer
PR NewswireGroundbreaking nipocalimab study of pregnant individuals at high risk for early onset severe hemolytic disease of the fetus and newborn published in The New England Journal of Medicine
PR NewswireDARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet regimen approved in the U.S. for patients with newly diagnosed multiple myeloma who are transplant-eligible
PR NewswireJohnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression
PR NewswireHealth Canada Authorizes RYBREVANT® (amivantamab) in Combination with Carboplatin and Pemetrexed as the Only Targeted First-line Treatment Approved for Patients with Non-Small Cell Lung Cancer wit...
PR NewswireCARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study
PR NewswireNipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients
PR NewswireJohnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's disease
PR NewswireTREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction
PR NewswireSubcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer
PR NewswireLate-breaking results show nipocalimab significantly improves Sjögren's disease activity in a Phase 2 study
PR NewswireTALVEY® (talquetamab-tgvs) demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma
PR NewswireSarepta Therapeutics Set to Join S&P MidCap 400
PR NewswireCARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy
PR NewswireALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Shockwave Medical, Inc.
PR NewswireRYBREVANT® (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mu...
PR NewswireTECVAYLI® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma
PR NewswireAMBRX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ambrx Biopharma, Inc. - AMAM
PR NewswireCIBC introduces additional Canadian Depositary Receipts ("CDRs")
PR NewswireCIBC introduces additional Canadian Depositary Receipts ("CDRs")
PR NewswireKenvue Set to Join S&P 500; Advance Auto Parts to Join S&P SmallCap 600
PR NewswireKenvue Set to Join S&P 500
PR NewswireSteel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400
PR NewswireYouth at Risk of Being Left Behind in Asia Pacific Tuberculosis Response, Regional Forum Spotlights
RSSForm 4 200406
RSSForm SC TO-T 200406
RSSForm SC TO-C 200406
RSSForm 4 200406
RSSForm SC TO-C 200406
RSSForm 3 200406
RSSForm 4 200406

Johnson Johnson News

Johnson Johnson News: auf dieser Seite finden Sie alle Johnson Johnson News und Nachrichten zur Johnson Johnson Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Johnson Johnson News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Johnson Johnson News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.